We are live on ! Find out more
THRD

Third Harmonic Bio
THRD

Delisted

THRD was delisted on the 30th of July, 2025.

Back to rankings

96 hedge funds and large institutions have $463M invested in Third Harmonic Bio in 2024 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 37 increasing their positions, 19 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

95% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 19

92% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 13

14% more funds holding

Funds holding: 84 → 96 (+12)

7.36% less ownership

Funds ownership: 107.12% → 99.76% (-7.4%)

22% less capital invested

Capital invested by funds: $597M → $463M (-$134M)

Holders
96
Holders Change
+12
Holders Change %
+14.29%
% of All Funds
1.26%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
25
Increased
37
Reduced
19
Closed
13
Calls
$1K
Puts
–
Net Calls
+$1K
Net Calls Change
-$95K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$27.8M
2
DM
Deerfield Management
New York
+$12.7M
3
Millennium Management
Millennium Management
New York
+$6.96M
4
NCM
Nantahala Capital Management
Connecticut
+$6.24M
5
GA
General Atlantic
New York
+$5.15M

Top Sellers

1
BI
BVF Inc
California
-$24.8M
2
CC
Commodore Capital
New York
-$14M
3
AVLSA
Atlas Venture Life Science Advisors
Massachusetts
-$6.3M
4
Citadel Advisors
Citadel Advisors
Florida
-$6.25M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.33M
Name Holding Trade Value Shares
Change 		Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$107M -$6.3M -505,573 -5%
O
2
OrbiMed
New York
$59.5M – – –
GA
3
General Atlantic
New York
$34.7M +$5.15M +413,561 +14%
EC
4
EcoR1 Capital
California
$32.7M – – –
T. Rowe Price Investment Management
5
T. Rowe Price Investment Management
Maryland
$30.1M +$1.24M +99,250 +4%
Fidelity Investments
6
Fidelity Investments
Massachusetts
$26.1M +$27.8M +2,228,549 +724%
TCM
7
TCG Crossover Management
California
$25.8M +$1.13M +90,424 +4%
BI
8
BVF Inc
California
$24.4M -$24.8M -1,993,000 -46%
BCM
9
Boxer Capital Management
California
$20.6M +$24.9M +2,000,000 New
BlackRock
10
BlackRock
New York
$15.2M +$251K +20,154 +1%
Vanguard Group
11
Vanguard Group
Pennsylvania
$10.6M +$1.72M +138,338 +16%
DM
12
Deerfield Management
New York
$10.5M +$12.7M +1,019,700 New
RCM
13
RA Capital Management
Massachusetts
$9.88M -$3.99M -320,206 -25%
Millennium Management
14
Millennium Management
New York
$6.59M +$6.96M +558,616 +686%
NCM
15
Nantahala Capital Management
Connecticut
$5.16M +$6.24M +501,000 New
Geode Capital Management
16
Geode Capital Management
Massachusetts
$4.96M +$518K +41,537 +9%
State Street
17
State Street
Massachusetts
$4.34M +$265K +21,301 +5%
T. Rowe Price Associates
18
T. Rowe Price Associates
Maryland
$3.73M +$4.51M +361,890 New
SSA
19
Schonfeld Strategic Advisors
New York
$3.32M +$821K +65,900 +26%
CC
20
Commodore Capital
New York
$2.45M -$14M -1,122,865 -83%
Northern Trust
21
Northern Trust
Illinois
$1.98M +$11.3K +903 +0.5%
Charles Schwab
22
Charles Schwab
California
$1.78M +$381K +30,611 +21%
Morgan Stanley
23
Morgan Stanley
New York
$1.67M -$6.14K -493 -0.3%
TCM
24
Tang Capital Management
California
$1.54M +$1.87M +150,000 New
Renaissance Technologies
25
Renaissance Technologies
New York
$1.31M +$287K +23,046 +22%
1
2 3 4 5

THRD Hedge Fund Activity: Q4 2024 in Review

96 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Third Harmonic Bio (THRD) for Q4 2024, worth a combined $463M — down 22% from $597M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new THRD positions and 13 closed out — a net gain of 12 holders — while 37 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $27.8M. The largest seller was BVF Inc, cutting an estimated $24.8M.

  • 96 institutional investors held Third Harmonic Bio (THRD) as of Q4 2024, up from 84 in Q3 2024.
  • Funds reported $463M of Third Harmonic Bio stock for Q4 2024, down 22% quarter-over-quarter.
  • 25 funds opened new Third Harmonic Bio positions in Q4 2024 and 13 closed out, a net change of +12 holders.
  • The largest Third Harmonic Bio buyer in Q4 2024 was Fidelity Investments, an estimated $27.8M added.
  • The largest Third Harmonic Bio seller in Q4 2024 was BVF Inc, an estimated $24.8M sold.

Based on aggregated 13F filings for Q4 2024.